CISATRACURIUM BESYLATE INJECTION SINGLE DOSE SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

CISATRACURIUM (CISATRACURIUM BESYLATE)

זמין מ:

FRESENIUS KABI CANADA LTD

קוד ATC:

M03AC11

INN (שם בינלאומי):

CISATRACURIUM

כמות:

2MG

טופס פרצבטיות:

SOLUTION

הרכב:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

10X5ML

סוג מרשם:

Prescription

איזור תרפויטי:

NEUROMUSCULAR BLOCKING AGENTS

leaflet_short:

Active ingredient group (AIG) number: 0133260001; AHFS:

מצב אישור:

APPROVED

תאריך אישור:

2015-07-16

מאפייני מוצר

PRODUCT MONOGRAPH
PR CISATRACURIUM BESYLATE INJECTION SINGLE-DOSE
Solution for injection (preservative-free)
2 mg/mL cisatracurium
PR CISATRACURIUM BESYLATE INJECTION MULTI–DOSE
Solution for injection (preserved)
2 mg/mL cisatracurium
Non-depolarizing Skeletal Neuromuscular Blocking Agent
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH ITS
ACTIONS, CHARACTERISTICS, AND HAZARDS.
FRESENIUS KABI CANADA LTD.
45 Vogell Road, Suite 200
Richmond Hill, ON
L4B 3P6 Canada
Date of Preparation:
July 7, 2015
Control Number 184996
_ _
_Cisatracurium-PM-ENG-v1.0_
_ _
_Page 2 of 37_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................27
SPECIAL HANDLING INSTRUCTIONS
.......................................................................28
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................2